BackX4 Pharmaceuticals Overview
X4 Pharmaceuticals Inc

X4 Pharmaceuticals Target Price

Analysts' average 12-month price target for X4 Pharmaceuticals is $12.

Get informed when a big investor buys or sells

+ Follow

Share Price

$3.5

Average Target Price

$11.50228.6% upside

2 analysts in the last 4 months

High: $12 | Low: $11

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-10Wells Fargo$11214.3% upsideOpen
2026-06-02Leerink PartnersThomas Smith$12242.9% upsideOpen
2026-03-09Guggenheim$12242.9% upsideOpen
2025-12-05Stifel NicolausJames Condulis$10185.7% upsideOpen
2025-11-05Stifel NicolausStephen Willey$7.5114.3% upsideOpen
2025-08-29Stifel NicolausStephen Willey$9157.1% upsideOpen
2025-08-13H.C. WainwrightSwayampakula Ramakanth$3.50% upsideOpen
2022-12-22Cantor Fitzgerald$314.3% downsideOpen
2022-12-11Piper SandlerEdward Tenthoff$314.3% downsideOpen
2022-11-30H.C. Wainwright$542.9% upsideOpen

X4 Pharmaceuticals (XFOR) FAQ

X4 Pharmaceuticals's target price stands at $12. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $12 for XFOR implies 228.6% upside versus today's price ($3.5). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how X4 Pharmaceuticals's target price evolved across reporting periods, while the comparison chart places XFOR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. X4 Pharmaceuticals's reading of $12 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.